CA2906378C - Controlled release pharmaceutical dosage forms - Google Patents

Controlled release pharmaceutical dosage forms Download PDF

Info

Publication number
CA2906378C
CA2906378C CA2906378A CA2906378A CA2906378C CA 2906378 C CA2906378 C CA 2906378C CA 2906378 A CA2906378 A CA 2906378A CA 2906378 A CA2906378 A CA 2906378A CA 2906378 C CA2906378 C CA 2906378C
Authority
CA
Canada
Prior art keywords
dosage form
doxycycline
controlled release
weight
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2906378A
Other languages
English (en)
French (fr)
Other versions
CA2906378A1 (en
Inventor
Sajeev Chandran
Shirishkumar Kulkarni
Pravin Meghrajji Bhutada
Ashish Ashokrao Deshmukh
Douglas BAKAN
Mitchell Wortzman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicis Pharmaceutical Corp
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Publication of CA2906378A1 publication Critical patent/CA2906378A1/en
Application granted granted Critical
Publication of CA2906378C publication Critical patent/CA2906378C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2906378A 2013-03-15 2014-03-04 Controlled release pharmaceutical dosage forms Active CA2906378C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN304KO2013 2013-03-15
IN304/KOL/2013 2013-03-15
US13/890,173 US10842802B2 (en) 2013-03-15 2013-05-08 Controlled release pharmaceutical dosage forms
US13/890,173 2013-05-08
PCT/US2014/020251 WO2014149674A1 (en) 2013-03-15 2014-03-04 Controlled release pharmaceutical dosage forms

Publications (2)

Publication Number Publication Date
CA2906378A1 CA2906378A1 (en) 2014-09-25
CA2906378C true CA2906378C (en) 2021-06-22

Family

ID=54198667

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2906378A Active CA2906378C (en) 2013-03-15 2014-03-04 Controlled release pharmaceutical dosage forms

Country Status (8)

Country Link
US (1) US10842802B2 (enExample)
EP (1) EP2968179B1 (enExample)
JP (1) JP6417532B2 (enExample)
KR (1) KR102298473B1 (enExample)
CN (2) CN112007007A (enExample)
AU (1) AU2014237934B2 (enExample)
CA (1) CA2906378C (enExample)
WO (1) WO2014149674A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528983B2 (en) * 2014-05-12 2016-12-27 Anna Merritt Holmes Physicochemical modification and application of alginate gels for the controlled release of reagents in classical solution assays and microfluidic assays
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
EP3220899A1 (en) 2014-11-19 2017-09-27 Nestlé Skin Health SA Modified release doxycycline composition
ITUB20150279A1 (it) * 2015-03-09 2016-09-09 S I I T S R L Servizio Int Imballaggi Termosaldanti Sistema flottante per la cura dei sintomi delle affezioni gastriche
WO2021007487A1 (en) 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5000886A (en) 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
CA2205553C (en) 1994-12-16 2009-04-07 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
US6245350B1 (en) 1994-12-16 2001-06-12 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
JPH0995440A (ja) 1995-09-29 1997-04-08 Roussel Morishita Kk 徐放性製剤およびその製造方法
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
AU713276B2 (en) 1996-05-23 1999-11-25 Samyang Corporation Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5780055A (en) 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
PL337813A1 (en) 1997-06-11 2000-09-11 Procter & Gamble Coated tablet with a coating ensuring safe administration for upper portion of the gastrointestinal tract
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
WO1999048372A1 (en) 1998-03-23 1999-09-30 General Mills, Inc. Encapsulation of components into edible products
AU777977B2 (en) 1998-10-09 2004-11-04 General Mills Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
HK1044476B (zh) 1999-03-17 2010-09-17 第一制药株式会社 药物组合物
US20030077301A1 (en) 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
FR2811571B1 (fr) 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
EP1319399A1 (en) * 2000-09-19 2003-06-18 Daiichi Pharmaceutical Co., Ltd. Medicinal composition
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
IN192750B (enExample) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
CA2447008A1 (en) 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
EP1465591A1 (en) 2001-12-20 2004-10-13 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
CA2478121A1 (en) 2002-03-07 2003-09-18 Advancis Pharmaceutical Corporation Antibiotic composition
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
AUPS167602A0 (en) 2002-04-12 2002-05-16 F.H. Faulding & Co. Limited An improved modified release preparation
WO2003088906A2 (en) 2002-04-16 2003-10-30 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US8192749B2 (en) 2003-04-16 2012-06-05 Galderma Laboratories Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US20050266077A1 (en) 2002-06-20 2005-12-01 Royal Biomedical, Inc. Resorbable matrices with coatings for delivery of bioactive compounds
KR101041767B1 (ko) 2002-06-25 2011-06-17 다케다 야쿠힌 고교 가부시키가이샤 서방성 조성물의 제조 방법
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
EP1417958A1 (en) 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
ES2645930T3 (es) 2003-01-03 2017-12-11 Supernus Pharmaceuticals, Inc. Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2004087175A1 (en) 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
CA2521885C (en) 2003-04-07 2013-06-25 Shire Laboratories, Inc. Once daily formulations of tetracyclines
EP1617785A2 (en) 2003-04-14 2006-01-25 Shire Laboratories Inc. Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
WO2004112713A2 (en) 2003-06-20 2004-12-29 Royer Biomedical, Inc. Drug polymer complexes
NZ544826A (en) 2003-07-25 2008-07-31 Warner Chilcott Co Inc A doxycycline metal complex in a solid dosage form
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US20050049210A1 (en) 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
CN1893931B (zh) 2003-10-27 2011-07-20 陶氏康宁公司 局部用制剂及将活性剂传递给基底的方法
WO2005046651A1 (en) 2003-11-12 2005-05-26 Ranbaxy Laboratories Limited Liquid filled capsules of doxycycline
RU2331410C2 (ru) 2003-12-04 2008-08-20 Пфайзер Продактс Инк. Способ получения фармацевтических мультичастиц
DE10358748A1 (de) 2003-12-12 2005-07-14 Lts Lohmann Therapie-Systeme Ag Darreichungsform basierend auf vernetzten hydrophilen Polymeren
US7410480B2 (en) 2004-04-21 2008-08-12 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US8383154B2 (en) 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
US7906140B2 (en) 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
US20080161273A1 (en) 2004-10-20 2008-07-03 Galderma Research & Development Method of Using Adapalene in Acne Maintenance Therapy
WO2006045152A1 (en) 2004-10-29 2006-05-04 Mayne Pharma International Pty Ltd Improved tabletting process
US20060147491A1 (en) 2005-01-05 2006-07-06 Dewitt David M Biodegradable coating compositions including multiple layers
US9205047B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20100215744A1 (en) 2008-08-06 2010-08-26 Medicis Pharmaceutical Corporation Hydroxypropyl Substitution Used to Regulate Dissolution of a Chemical
US8920837B2 (en) 2005-07-01 2014-12-30 Rubicon Research Private Limited Sustained release dosage form
EP1898922A4 (en) 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
ZA200802602B (en) 2005-08-24 2009-10-28 Rubicon Res Pvt Ltd Controlled release formulation
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US20080318910A1 (en) * 2005-10-04 2008-12-25 Mistral Pharma, Inc. Controlled-Release Oral Dosage Form
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
EP1991236A2 (en) 2006-01-24 2008-11-19 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
PL2457563T3 (pl) 2006-05-09 2017-09-29 Mallinckrodt Llc Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego
CA2655596C (en) 2006-06-27 2011-10-25 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
US20080014257A1 (en) 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
WO2008058288A2 (en) 2006-11-09 2008-05-15 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
PL2120963T3 (pl) 2006-12-21 2019-05-31 Paratek Pharm Innc Podstawione związki tetracyklinowe do leczenia zaburzeń zapalnych skóry
GB0703627D0 (en) 2007-02-24 2007-04-04 Agt Sciences Ltd Aqueous formulations
US20100016322A1 (en) 2007-02-28 2010-01-21 Nagesh Nagaraju Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
JP5395052B2 (ja) 2007-03-23 2014-01-22 モレキュラー リサーチ センター インコーポレイテッド 炎症を処置するための組成物および方法
WO2009009135A1 (en) 2007-07-11 2009-01-15 Dow Corning Corporation Compositions for delivering a drug
CN101380474B (zh) 2007-09-06 2012-07-25 北京大学 用于口服制剂的pH敏感性固体药物组合物及制备方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
EP2133071A1 (en) 2008-06-09 2009-12-16 Université de la Méditerranée Process for making gastroretentive dosage forms
US20100305309A1 (en) 2009-05-28 2010-12-02 Northwestern University Nanodiamond particle complexes
EP2299953B1 (en) 2008-07-14 2017-04-12 Polypid Ltd. Sustained-release drug carrier composition
WO2010017215A2 (en) 2008-08-04 2010-02-11 The Regents Of The University Of California Biodegradable microspheres and methods of use thereof
WO2010033800A2 (en) 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
BRPI0919010A2 (pt) 2008-09-22 2015-08-18 Rubicon Res Private Ltd Composições exibindo trânsito retardado através do trato gastrointestinal.
DE102008048729A1 (de) 2008-09-24 2010-03-25 Add Technologies Ltd Advanced Drug Delivery Multipartikuläre Tabletten und Verfahren zur deren Herstellung
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
WO2010037545A1 (en) 2008-10-02 2010-04-08 Bayer Consumer Care Ag Compositions for treating or alleviating skin diseases or disorders related to an enhanced level of anti-microbial peptides and proteins
WO2010038234A1 (en) 2008-10-02 2010-04-08 Taro Pharmaceutical Industries Ltd. Combination product of spironolactone and doxycycline
US9498431B2 (en) 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
CN102307576A (zh) 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
US20120045504A1 (en) 2009-04-14 2012-02-23 Kathryn Whitehead oral drug devices and drug formulations
GB0907019D0 (en) 2009-04-24 2009-06-03 Oxford Nutrascience Ltd Pharmaceutical,therapeutic or nutritional delivery systems for functional ingredients
US20100291201A1 (en) 2009-05-14 2010-11-18 Cerovene, Inc. Coated pharmaceutical capsule dosage form
WO2011044208A1 (en) 2009-10-06 2011-04-14 Scott Dorfner Antibiotic formulations providing reduced gastrointentestinal side effects
ES2752008T3 (es) 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
US9327105B2 (en) 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
WO2011133217A1 (en) 2010-04-21 2011-10-27 Pharmacline, Llc Topical drug delivery system with dual carriers
ES2918299T3 (es) 2010-06-11 2022-07-15 Prec Dermatology Inc Composiciones de espuma a base de aerosol emoliente con alto contenido de aceite
MX2013004227A (es) 2010-10-21 2013-05-30 Galderma Sa Tableta de liberacion sostenida y proceso para prepararla.
US8652516B1 (en) 2013-03-15 2014-02-18 Cerovene, Inc. Doxycycline formulations, and methods of treating rosacea

Also Published As

Publication number Publication date
EP2968179A4 (en) 2016-08-31
JP6417532B2 (ja) 2018-11-07
US20140274970A1 (en) 2014-09-18
WO2014149674A1 (en) 2014-09-25
EP2968179A1 (en) 2016-01-20
KR20160021074A (ko) 2016-02-24
US10842802B2 (en) 2020-11-24
KR102298473B1 (ko) 2021-09-03
AU2014237934B2 (en) 2019-01-24
CA2906378A1 (en) 2014-09-25
JP2016516031A (ja) 2016-06-02
CN112007007A (zh) 2020-12-01
CN105188683A (zh) 2015-12-23
EP2968179B1 (en) 2019-11-06
AU2014237934A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
EP2011486B1 (en) Pharmaceutical compositions of rifaximin
CN101636152B (zh) 含有西洛他唑的控释制剂及其制备方法
KR101643219B1 (ko) 40-o-(2-히드록시)에틸-라파마이신을 포함하는 제약 조성물
US9387178B2 (en) Modified release tranexamic acid formulation
US20040033262A1 (en) Sustained release pharmaceutical composition of a cephalosporin antibiotic
EP1711169B1 (en) Extended release coated minitablets of venlafaxine hydrochloride
AU2014237934B2 (en) Controlled release pharmaceutical dosage forms
KR20060136409A (ko) 벤라팍신 히드로클로라이드의 방출연장형 코팅 미니정제
WO2004016250A1 (en) Sustained release pharmaceutical composition of a cephalosporin antibiotic
WO2020101586A1 (en) Controlled release propiverine formulations
US20040096496A1 (en) Sustained release pharmaceutical composition of a cephalosporin antibiotic
HK40041911A (en) Controlled release pharmaceutical dosage forms
RU2603469C2 (ru) Таблетка с контролируемым высвобождением для перорального введения и способ ее приготовления
EP1534246B1 (en) Sustained release pharmaceutical composition of a cephalosporin antibiotic
US20080206338A1 (en) Controlled release formulations of an alpha-adrenergic receptor antagonist
HK1091137B (en) Extended release coated minitablets of venlafaxine hydrochloride
CN101784264A (zh) 用于延长释放的药物制剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190219

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250919

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260219